SCHEMBL31486261

SCHEMBL31486261

CCc1cc(CNc2ncc3n(c2=O)[C@H](C(=O)O)CC3)cc(-c2ccccc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.37
PREP P48147 2/20 0.35
GRIN2B Q13224 2/20 0.35
FFAR1 O14842 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
CCNE2 O96020 1/20 0.33
CCNA2 P20248 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
RAD52 P43351 1/20 0.33
OGFRL1 Q5TC84 3/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
KMT2A Q03164 1/20 0.33
F2 P00734 1/20 0.33
LOXL2 Q9Y4K0 2/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31486336 0.89 AOC3 (0.42) MAPK14PREPFFAR1OGFRL1OPRM1
SCHEMBL31486475 0.85 PREP (0.43) MAPK14PREPOGFRL1OPRM1OPRK1
SCHEMBL31486384 0.82 MAPK14 (0.35) MAPK14PREPGRIN2BOGFRL1OPRM1
SCHEMBL31486332 0.79 BCHE (0.37) MAPK14PREPOGFRL1OPRM1OPRK1
SCHEMBL6073947 0.78 ACE (0.35) PREPF2ALDH1A1CYP1A2CYP2D6
SCHEMBL31486546 0.78 RPS6KB1 (0.39) MAPK14PREP
SCHEMBL31486227 0.78 JAK3 (0.43) PREPALDH1A1HPGD
SCHEMBL31486369 0.78 PTK2 (0.42)
SCHEMBL7995908 0.77 F2 (0.48) MAPK14PREPF2
SCHEMBL31486305 0.77 MAPK14 (0.37) MAPK14PREPHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122225-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-17 US disclosed
WO-2025076476-A2 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122225-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, SPINT2, SERPINB1 MAPK14 2151/4885PREP 140/4885GRIN2B 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.